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Sequencing studies are increasingly being conducted to identify rare variants associated with complex traits. The limited power of clas-
sical single-marker association analysis for rare variants poses a central challenge in such studies. We propose the sequence kernel asso-
ciation test (SKAT), a supervised, flexible, computationally efficient regression method to test for association between genetic variants(common and rare) in a region and a continuous or dichotomous trait while easily adjusting for covariates. As a score-based vari-
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mance-component test, SKAT can quickly calculate p values analyti
so can easily be applied to genome-wide data. Using SKAT to analyz
ing the whole genome into 30 kb regions, requires only 7 hr on a
practical scenarios and triglyceride data from the Dallas Heart Study
rare-variant association tests. We also provide analytic power and sa
and whole-genome sequence association studies.
Introduction
Genome-wide association studies (GWASs) have identified
more than 1000 genetic loci associated with many human
diseases and traits,1 yet common variants identified
through GWASs often explain only a small proportion of
trait heritability. The advent of massively parallel
sequencing2 has transformed human genetics3,4 and has
the potential to explain some of this missing heritability
through identification of trait-associated rare variants.5
Although considerable resources have been devoted to
sequence mapping and genotype calling,6–9 successful
application of sequencing to the study of complex traits
requires novel statistical methods that allow researchers
to test efficiently for association given data on rare vari-
ants10 and to perform sample-size and power calculations
to help design sequencing-based association studies.
Rare genetic variants, here defined as alleles with
a frequency less than 1%–5%, can play key roles in influ-
encing complex disease and traits.11 However, standard
methods used to test for association with single common
genetic variants are underpowered for rare variants unless
sample sizes or effect sizes are very large.12,13 A logical alter-
native approach is to employ burden tests that assess
the cumulative effects of multiple variants in a genomicregion.12–18 Burden tests proposed to date are based on
collapsing or summarizing the rare variants within a region
by a single value, which is then tested for association with
the trait of interest. For example, the cohort allelic sum test
(CAST)14 collapses information on all rare variants within
a region (e.g., the exons of a gene) into a single dichoto-
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a genome-wide sequencing study of 1000 individuals, by segment-
aptop. Through analysis of simulated data across a wide range of
e show that SKAT can substantially outperform several alternative
ple-size calculations to help design candidate-gene, whole-exome,
mous variable for each subject by indicating whether or
not the subject has any rare variants within the region
and then applies a univariate test. Instead of collapsing by
dichotomizing the number of rare variants within a region,
collapsing by counting them is also possible.18 The
combined multivariate and collapsing method12 extends
CAST by collapsing rare variants within a region into
subgroups on the basis of allele frequency, collapsing
subgroups as in CAST, and applying a multivariate test to
the subgroups. The weighted sum test (WST)13 specifically
considers the case-control setting and collapses a set of
SNPs into a single weighted average of the number of
rare alleles for each individual. Numerous alternative
methods are largely variations on these approaches.16,17,19
A limitation for all these burden tests is that they implic-
itly assume that all rare variants influence the phenotype
in the same direction and with the same magnitude of
effect (after incorporating known weights). However, one
would expect most variants (common or rare) within
a sequenced region to have little or no effect on pheno-
type, whereas some variants are protective and others dele-
terious, and the magnitude of each variant’s effect is likely
to vary (e.g., rarer variants might have larger effects).
Hence, collapsing across all variants is likely to introduce
substantial noise into the aggregated index, attenuateevidence for association, and result in power loss. Further-
more, burden tests require either specification of thresh-
olds for collapsing or the use of permutation to estimate
the threshold.16–20 Permutation tests are computationally
expensive, especially on the whole-genome scale, and are
difficult for covariate adjustment because permutation
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requires independence between the genotype and the co-
variates.
The recently proposed C-alpha test21 is a non-burden-
based test and is hence robust to the direction and magni-
tude of effect. For case-control data, it compares the
expected variance to the actual variance of the distribution
of allele frequencies. These important advantages allow the
C-alpha test to have improved power over burden-based
tests, especially when the effects are in different directions.
Despite these attractive features, the C-alpha test does not
allow for easy covariate adjustment, such as for controlling
population stratification, which is important in genetic
association studies. The C-alpha test also uses permutation
to obtain a p value when linkage disequilibrium is present
among the variants, which is, as noted earlier, computa-
tionally expensive for whole-genome experiments. The
approach has not been generalized to analysis of contin-
uous phenotypes.
We propose in this paper the sequence kernel association
test (SKAT), a flexible, computationally efficient, regression
approach that tests for association between variants in a
region (both common and rare) and a dichotomous (e.g.,
case-control) or continuous phenotype while adjusting for
covariates, such as principal components, to account for
population stratification.22 The kernel machine regression
framework was previously considered for common vari-
ants.23,24 In this paper, weprovide several essentialmethod-
ological improvements necessary for testing rare variants.
SKAT uses a multiple regression model to directly regress
the phenotype on genetic variants in a region and on cova-
riates, and so allows different variants to have different
directions and magnitude of effects, including no effects;
SKAT also avoids selection of thresholds. We develop a
kernel association test to test the regression coefficients of
the variants by using a variance-component score test in a
mixed-model framework by accounting for rare variants.
SKAT is computationally efficient. This quality is espe-
cially important in genome-wide studies because SKAT
only requires fitting the null model in which phenotypes
are regressed on the covariates alone; p values are easily
computed with simple analytic formulae. Additional
features of SKAT include exploitation of local correlation
structure, incorporation of flexible weights to boost power
(e.g., by increasing the weight of rarer variants or incorpo-
rating functionality), and allowance for epistatic variant
effects. As discussed in more detail below, under special
cases, the SKAT, C-alpha test, and individual variant test
statistics are closely related.
We demonstrate through simulation and analysis of
resequencing data from the Dallas Heart Study that SKAT
is often more powerful than existing tests across a broad
range of models for both continuous and dichotomous
data. We also investigate the factors that influence power
for sequence association studies. Finally, we describe
analytic tools to estimate statistical power and sample sizesto guide the design of new sequence association studies of
rare variants with SKAT.
TheMaterial and Methods
Sequencing Kernel Association Test
SKAT is a supervised test for the joint effects of multiple variants in
a region on a phenotype. Regions can be defined by genes (in
candidate-gene or whole-exome studies) or moving windows
across the genome (in whole-genome studies). For each region,
SKAT analytically calculates a p value for association while adjust-
ing for covariates. Adjustments for multiple comparisons are
necessary for analyzing multiple regions, for example with the
Bonferroni correction or FDR control.
Notation
Assume n subjects are sequenced in a region with p variant sites
observed. Covariates might include age, gender, and top principal
components of genetic variation for controlling population strat-
ification.22 For the i-th subject, yi denotes the phenotype variable,
Xi¼ (Xi1, Xi2, .., Xim) denotes the covariates, andGi¼ (Gi1, Gi2,.,
Gip) denotes the genotypes for the p variants within the region.
Typically, we assume an additive genetic model and let Gij, ¼ 0,
1, or 2 represent the number of copies of the minor allele. Domi-
nant and recessive models can also be considered.
SKAT Model and Test for Linear SNP Effects
For a simple illustration of SKAT, we focus here on testing for a rela-
tionship between the variants and the phenotype by using clas-
sical multiple linear and logistic regression. We describe how the
SKAT can incorporate epistatic effects later. To relate the sequence
variants in a region to the phenotype, consider the linear model
yi ¼ a0 þ a0Xi þ b0Gi þ 3i; (Equation 1)
when the phenotypes are continuous traits, and the logistic model
logit P

yi ¼ 1
 ¼ a0 þ a0Xi þ b0Gi; (Equation 2)
when the phenotypes are dichotomous (e.g., y ¼ 0/1 for case or
control). Here a0 is an intercept term, a ¼ [a1,., am]’ is the vector
of regression coefficients for them covariates, b ¼ [b1,.,bp]’ is the
vector of regression coefficients for the p observed gene variants in
the region, and for continuous phenotypes 3i is an error term with
a mean of zero and a variance of s2. Under both linear and logistic
models, and evaluating whether the gene variants influence the
phenotype, adjusting for covariates, corresponds to testing the
null hypothesis H0: b ¼ 0, that is, b1 ¼ b2 ¼. ¼ bp ¼ 0. The stan-
dard p-DF likelihood ratio test has little power, especially for rare
variants. To increase the power, SKAT tests H0 by assuming each
bj follows an arbitrary distribution with a mean of zero and
a variance of wjt, where t is a variance component and wj is a pre-
specified weight for variant j. One can easily see that H0: b ¼ 0 is
equivalent to testing H0: t ¼ 0, which can be conveniently tested
with a variance-component score test in the corresponding mixed
model; this is known to be a locally most powerful test.25 A key
advantage of the score test is that it only requires fitting the null
model yi ¼ a0 þ a1’Xi þ 3i for continuous traits and the logit
P(yi ¼ 1) ¼ a0 þ a1’Xi for dichotomous traits.
Specifically, the variance-component score statistic is
Q ¼ y bm0Ky bm; (Equation 3)
where K ¼ GWG’, bm is the predicted mean of y under H0, that isbm ¼ ba0 þXba for continuous traits and bm ¼ logit1ðba0 þXbaÞ for
dichotomous traits; and ba0 and ba are estimated under the null
model by regressing y on only the covariates X. Here G is an
n 3 p matrix with the (i, j)-th element being the genotype of
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variant j of subject i, andW¼ diag(w1,., wp) contains the weights
of the p variants.
In fact, K is an n 3 n matrix with the (i, i’)-th element equal to
KðGi;Gi0 Þ ¼
Pp
j¼1wjGijGi 0 j. Kð,; ,Þ is called the kernel function, and
KðGi;Gi0 Þmeasures the genetic similarity between subjects i and i’
in the region via the p markers. This particular form of Kð,; ,Þ is
called the weighted linear kernel function. We later discuss other
choices of the kernel to model epistatic effects.
Good choices of weights can improve power. Each weight wj
is prespecified, with only the genotypes, covariates and external
biological information, that is estimated without using the
outcome, and reflects the relative contribution of the j-th variant
to the score statistic: if wj is close to zero, then the j-th variant
makes only a small contribution to Q. Thus, decreasing the
weight of noncausal variants and increasing the weight of
causal variants can yield improved power. Because in practice
we do not know which variants are causal, we propose to setﬃﬃﬃﬃﬃ
wj
p ¼ BetaðMAFj; a1; a2Þ, the beta distribution density function
with prespecified parameters a1 and a2 evaluated at the sample
minor-allele frequency (MAF) (across cases and controls
combined) for the j-th variant in the data. The beta density is flex-
ible and can accommodate a broad range of scenarios. For
example, if rarer variants are expected to be more likely to have
larger effects, then setting 0 < a1 % 1 and a2 R 1 allows for
increasing the weight of rarer variants and decreasing the weight
of commonweights.We suggest setting a1¼ 1 and a2¼ 25 because
it increases the weight of rare variants while still putting decent
nonzero weights for variants with MAF 1%–5%. All simulations
were conducted with this default choice unless stated otherwise.
Note that a smaller a1 results in more strongly increasing
the weight of rarer variants. Examples of weights across a range
of a1 and a2 values are presented in Figure S1, available online.
Note that a1 ¼ a2 ¼ 1 corresponds to wj ¼ 1, that is all variants
are weighted equally, and a1 ¼ a2 ¼ 0.5 corresponds toﬃﬃﬃﬃﬃ
wj
p ¼ 1= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃMAFjð1MAFjÞp , that iswj is the inverse of the variance
of the genotype of marker j, which puts almost zero weight for
MAFs > 1% and can be used if one believes only variants with
MAF < 1% are likely to be causal. Note that SKAT calculated
with this weight is identical to the unweighted SKAT test with
the standardized genotypes in Equations 1 and 2. Other forms of
the weight as a function of MAF can also be used. Because SKAT
is a score test, the type I error is protected for any choice of pre-
chosen weights. Note that the weights used in the weighted sum
test13 involve phenotype information and will therefore alter
the null distribution of SKAT if such weights are used.
Under the null hypothesis, Q follows a mixture of chi-square
distributions, which can be closely approximated with the compu-
tationally efficient Davies method.26 See Appendix A for details.
A special case of SKAT arises when the outcome is dichotomous,
no covariates are included, and all wj ¼ 1. Under these conditions,
we show in Appendix A that the SKAT test statistic Q is equivalent
to the C-alpha test statistic T. Hence, the C-alpha test can be
seen as a special case of SKAT, or alternatively, SKAT can be seen
as a generalized C-alpha test that does not require permutation
but calculates the p value analytically, allows for covariate adjust-
ment, and accommodates either dichotomous or continuous
phenotypes. Because SKAT under flat weights is also equivalent
to the kernel machine regression test23,24 and because the kernel
machine regression test is in turn related to the SSU test,27 it
follows transitively that SKAT under flat weights, the kernelmachine regression test, the SSU test, and the C-alpha test are all
equivalent and special cases of SKAT. Note that the null distribu-
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more accurate analytic p values, especially in the extreme tail,
when sample sizes are sufficient.
Relationship between Linear SKAT and Individual Variant Test Statistics
One can efficiently compute the test statistic Q by exploiting
a close connection between the SKAT score test statistic Q and
the individual variant test statistics. In particular, Q is a weighted
sum of the individual score statistics for testing for individual
variant effects. Hence, by letting gj ¼ [G1j, G1j, ., Gnj]’ denote
the n 3 1 vector containing the genotypes of the n subjects for
variant j, it is straightforward to see that Q ¼Ppj¼1wjS2j , where
Sj ¼ g0jðy bm0Þ is the individual score statistic for testing the
marginal effect of the j-th marker (H0: bj ¼ 0) under the individual
linear or logistic regression model of yi on Xi and only the j-th
variant Gij:
yi ¼ a0 þX0i aþ bjGij þ 3i
for continuous phenotypes and
logit P

yi ¼ 1
 ¼ a0 þX0i aþ bjGij
for dichotomous phenotypes. bm0 is estimated as bm0 ¼ ba0 þX0i ba
for continuous traits and bm0 ¼ logit1ðba0 þX0i baÞ for dichotomous
traits. As a score test, one needs to fit the null model only a single
time to be able to compute the Sj for all individual variants j as well
as all regions to be tested. Similarly, if multiple regions are under
consideration, then the same bm0 can be used to compute the
SKAT Q statistics for each region.
Accommodating Epistatic Effects and Prior Information under the SKAT
An attractive feature of SKAT is the ability to model the epistatic
effects of sequence variants on the phenotype within the flexible
kernel machine regression framework.28–30 To do so, we replace
Gi’b by a more flexible function f(Gi) in the linear and logistic
models (1) and (2) where f(Gi) allows for rare variant by rare
variant and common variant by rare-variant interactions. Specifi-
cally, for continuous traits we use the semiparametric linear
model23,29
yi ¼ a0 þ a0Xi þ f ðGiÞ þ 3i; (Equation 4)
and for dichotomous traits, we use the semiparametric logistic
model24,30
logit P

yi ¼ 1
 ¼ a0 þ a0Xi þ f ðGiÞ: (Equation 5)
Here the variants, Gi, are related to the phenotype through
a possibly nonparametric function f($), which is assumed to lie
in a functional space generated by a positive semidefinite kernel
function Kð,; ,Þ. Models (1) and (2) assume linear genetic effects
and are specified by KðGi;Gi0 Þ ¼
Pp
j¼1wjGijGi 0 j. By changing
Kð,; ,Þ, one can allow for more complex models. Intuitively,
KðGi;Gi0 Þ is a function that measures genetic similarity between
the i-th and i’-th subjects via the p variants in the region, and
any positive semidefinite function KðGi;Gi0 Þ can be used as
a kernel function. We tailored several useful and commonly used
kernels specifically for the purpose of rare-variant analysis: the
weighted linear kernel, the weighted quadratic kernel, and the
weighted identity by state (IBS) kernel.
The weighted linear kernel function KðGi;Gi0 Þ ¼
Pp
j¼1wjGijGi0 j
implies that the trait depends on the variants in a linear fashion
and is equivalent to the classical linear and logistic model pre-
sented in Equations 1 and 2. The weighted quadratic kernelPp 2KðGi;Gi0 Þ ¼ ð1þ j¼1wjGijGi0 jÞ implicitly assumes that the model
depends on the main effects and quadratic terms for the gene
variants and the first-order variant by variant interactions. The
weighted IBS kernel KðGi;Gi0 Þ ¼
Pp
j¼1wjIBSðGij;Gi0 jÞ, defines simi-
larity between individuals as the number of alleles that share
IBS. For additively coded autosomal genotype data, KðGi;Gi0 Þ ¼Pp
j¼1wjð2 jGij Gi0 jjÞ. The model implied by the weighted IBS
kernel models the SNP effects nonparametrically.31 Consequently,
this allows for epistatic effects because the function f($) does not
assume linearity or interactions of a particular order (e.g., the
second order), Using the weighted IBS kernel removes the assump-
tion of additivity because the number of alleles that are identical
by state is a physical quantity that does not change on the basis
of different genotype encodings.
We note that a kernel function that better captures both the
similarity between individuals and the causal variant effects will
increase power. In particular, if relationships are linear and no
interactions are present, then the weighted linear kernel will
have highest power. If interactions are present, the weighted
quadratic and weighted IBS kernels can increase power. Our expe-
rience suggests using the IBS kernel when the number of interact-
ing variants within the region is modest. As our understanding of
genetic architecture improves so too will our knowledge of which
kernel to use.
In each of the above kernels, wj is an allele specific weight that
controls the relative importance of the jth variant and might be
a function of factors such as allele frequency or anticipated func-
tionality. Without prior information, we suggest the use of theﬃﬃﬃﬃﬃ
wj
p ¼ BetaðMAFj;1;25Þ suggested earlier. However, if prior infor-
mation is available, for example some variants are predicted as
functional or damaging via Polyphen32 or Sift,33 weights can be
selected to increase the weight for likely functionality.
To test for the effects of gene variants in a region on a phenotype,
one tests the null hypothesis H0: f(G) ¼ 0. SKAT tests for this null
hypothesis by assuming the n 3 1 vector f ¼ [f(G1),., f(Gn)]’ for
the genetic effects of n subjects follows a distribution with mean
zero and covariance tK, where t is a variance component that
indexes the effects of the variants.29,30 Hence, we can test the
null hypothesis that corresponds to testing H0: t ¼ 0 by a vari-
ance-component score test. In particular, we simply replace K in
Equation 3 by using the K discussed in this section, for example,
the weighted IBS kernel, for epistatic effect. All subsequent calcu-
lations for computing a p value remain the same.
Because the SKAT evaluates significance via a score test, which
operates under the null hypothesis, the SKAT is valid (in terms
of protecting type I error) irrespective of the kernel and the
weights used. Good choices of the kernel and the weights simply
increase power.
Planning New Sequencing-Based Association Studies:
Estimation of Power and Sample Size
Power and sample-size calculations are important in designing
sequencing studies of complex traits. Using a modification of
the higher-order moment-approximation method,34 we provide
an analytic method to carry out efficiently such calculations for
SKAT.35 Specifically, for a fixed sample size and a level, given a prior
hypothesis on the genetic architecture of a particular region, the
effect size, and the proportion and number of causal variants
within a region, our method provides the power to detect the
region as significant with SKAT. Similarly, if the desired power is
fixed, the approach can be used to find the necessary sample size.
There are key differences between the power and sample-sizeestimation for single-variant- and region (set)-based tests. For
a region (set)-based test, the power depends strongly on the under-
Thelying genetic architecture, and its estimation requires modeling
this genetic architecture and the linkage disequilibrium (LD)
between variants. Therefore, to estimate power to detect a partic-
ular region as associated with a phenotype requires specification
of the significance level, sample size, which variants in the region
are causal with corresponding effect size, and the LD structure of
the variants in the region. Ideally, one could use prior data to
assess the LD and MAF. Because prior data can be difficult to
obtain, we currently recommend the use of either 1000 Genomes
Project data36 or data simulated under a population genetics
model.37 Relevant preliminary data will become increasingly
available as sequencing studies become more common.
Our SKAT software uses simulated data based on the coalescent
population genetic model (released with the software package) as
a default in performing sample-size and power calculations, and
instead of directly specifying the effects of any given variant, the
user can input an MAF threshold for determining which variants
are regarded as rare and also a proportion determining how many
of the rare variants are causal. The causal variants are then randomly
selected from the alleles with true MAF (based on simulated or
preliminary data) less than the threshold. The magnitudes of the
effects jbjj for causal variants are set to be equal to c 3 jlog10 MAFj
where c is determined on the basis of the maximum effect size the
user would like to allow (described below in the power simulations
section) at MAF ¼ 104. This allows the effects of causal variants to
decrease with MAFs. Because these parameters can be difficult to
choose as apriori, powerandsample size canbe reasonably estimated
by averaging results over a range of parameter values. Similarly,
because the regional architecture can vary across different regions,
for genome-wide studies, one can average over multiple randomly
selected regions as currently implemented in the SKAT software.
Numerical Experiments and Simulations
To validate SKAT in terms of protecting type I error and to assess its
power compared to burden tests and the accuracy of our power
and sample-size tools, we carried out simulation studies under
a range of configurations. For all simulations, we determined
sequence genotypes by simulating 10,000 chromosomes for a
1 Mb region on the basis of a coalescent model that mimics the
LD pattern local recombination rate and the population history
for Europeans by using COSI.37
Type I Error Simulations
To investigate whether SKAT preserves the desired type I error rate
at the near genome-wide threshold level, for example a ¼ 106, it
is necessary to conduct simulations with hundreds of millions of
simulated datasets. Although SKAT is computationally efficient,
generating such a large number of datasets is challenging. To
reduce the computation burden, we took the following approach.
Using 10,000 randomly selected sets of 30 kb subregions within
a 1 Mb chromosome, we first generated 10,000 sets of genotypes
G(n 3 p) from the coalescent model, with p variants on n subjects.
Then, for each of the 10,000 simulated genotype data sets, we
simulated 10,000 sets of continuous phenotypes such that we
were able to obtain 108 individual genotype-phenotype data sets
by using the model:
y ¼ 0:5X1 þ 0:5X2 þ 3;
where X1 is a continuous covariate generated from a standard
normal distribution, X2 is a dichotomous covariate taking values
0 and 1 with a probability of 0.5, and 3 follows a standard normaldistribution. Note that the continuous trait values are not related
to the genotype so that the null model holds. The 30 kb regions on
American Journal of Human Genetics 89, 82–93, July 15, 2011 85
0.5k 1k 2.5k 5k0
.0
0.
2
0.
4
0.
6
0.
8
1.
0
β +/− = 100/0
Total Sample Size
Po
w
er
SKAT
SKAT_M
rSKAT
W
N
C
0.5k 1k 2.5k 5k0
.0
0.
2
0.
4
0.
6
0.
8
1.
0
β +/− = 80/20
Total Sample Size
Po
w
er
0.5k 1k 2.5k 5k0
.0
0.
2
0.
4
0.
6
0.
8
1.
0
β +/− = 50/50
Total Sample Size
Po
w
er
Continuous Trait
0.5k 1k 2.5k 5k0
.0
0.
2
0.
4
0.
6
0.
8
1.
0
β +/− = 100/0
Total Sample Size
Po
w
er
0.5k 1k 2.5k 5k0
.0
0.
2
0.
4
0.
6
0.
8
1.
0
β +/− = 80/20
Total Sample Size
Po
w
er
0.5k 1k 2.5k 5k0
.0
0.
2
0.
4
0.
6
0.
8
1.
0
β +/− = 50/50
Total Sample Size
Po
w
er
Dichotomous Trait
Figure 1. Simulation-Study-Based Power Comparisons of SKAT and Burden Tests
Empirical power at a¼ 106 under an assumption that 5% of the rare variants withMAF< 3%within random 30 kb regions were causal.
Top panel: continuous phenotypes with maximum effect size (jbj) equal to 1.6 when MAF ¼ 104; bottom panel: case-control studies
with maximum OR ¼ 5 when MAF ¼ 104. Regression coefficients for the s causal variants were assumed to be a decreasing function
of MAF as jbjj ¼ c jlog10MAFjj (j ¼ 1,.,p [see Figure S2]), where c was chosen to result in these maximum effect sizes. From left to right,
the plots consider settings in which the coefficients for the causal rare variants are 100% positive (0% negative), 80% positive (20% nega-
tive), and 50% positive (50%negative). Total sample sizes considered are 500, 1000, 2500, and 5000, with half being cases in case-control
studies. For each setting, six methods are compared: SKAT, SKAT in which 10% of the genotypes were set to missing and then imputed
(SKAT_M), restricted SKAT (rSKAT) in which unweighted SKAT is applied to variants with MAF < 3%, the weighted sum burden test (W)
with the sameweights as used by SKAT, counting-based burden test (N), and the CASTmethod (C). All the burden tests usedMAF< 3% as
the threshold. For each method, power was estimated as the proportion of p values < a among 1000 simulated data sets.which the genotype values are based contained 605 variants on
average, but the number of observed variants for any given data
set was considerably less and depended on the sample size n,
which we set to 500, 1000, 2500, and 5000.
We repeated the type I error simulations for dichotomous
phenotypes as above, except the dichotomous outcomes were
generated via the model:
logit Pðy ¼ 1Þ ¼ a0;
where a0 was determined to set the prevalence to 1% and case-
control sampling is used.
For both continuous and dichotomous simulations, we applied
SKAT by using the default weighted linear kernel to each of the 108
data sets and estimated the empirical type I error rate as the
proportion of p values less than a ¼ 104, 105, or 106.
We note that the estimated type I error from this approach isnot the same as the empirical type I error when genotypes are
generated randomly for each simulation, because for each of the
86 The American Journal of Human Genetics 89, 82–93, July 15, 201110,000 genotype data sets, only the outcomes are resampled.
However, our type I error estimator is still unbiased and results
in very accurate type I error estimates. For larger a levels (0.05
and 0.01), we directly computed the empirical type I error rate
by using data sets in which genotypes were randomly generated
for each simulation.
Empirical Power Simulations
We simulated data sets in which 30 kb subregions were randomly
selected from the generated 1 Mb chromosomes and used to
create causal variants and aphenotype variable aswell as additional
simulated covariates. We generated continuous phenotypes by
y ¼ 0:5X1 þ 0:5X2 þ b1Gc1 þ b2Gc2 þ.þ bpGcp þ 3;
where X1, X2, and 3 are as defined for the type I error simulations,
Gc1;G
c
2;.;G
c
s are the genotypes of the s causal rare variants (a
randomly selected subset of the simulated rare variants, forexample 5% of variants that have MAF < 3% in Figure 1), and
the bs are effect sizes for the causal variants. Similarly, we
Table 1. Type I Error Estimates of SKAT Aimed at Testing an Association between Randomly Selected 30 kb Regions with a Continuous
Trait at Type I Error Rates as Low as the Genome-wide a ¼ 106 Level
Total Sample Size (n)
Continuous Phenotypes Dichotomous Phenotypes
a ¼ 104 a ¼ 105 a ¼ 106 a ¼ 104 a ¼ 105 a ¼ 106
500 7.4 3 105 6.5 3 106 5.9 3 107 2.2 3 105 1.0 3 106 1.0 3 108
1000 8.5 3 105 8.2 3 106 8.0 3 107 5.0 3 105 3.5 3 106 2.3 3 107
2500 9.6 3 105 9.1 3 106 8.4 3 107 7.6 3 105 6.3 3 106 5.6 3 107
5000 9.8 3 105 9.6 3 106 8.8 3 107 8.9 3 105 7.8 3 106 7.0 3 107
Each entry represents type I error rate estimates as the proportion of p values a under the null hypothesis based on 108 simulated phenotypes.generated dichotomous phenotypes for case-control data under
the logistic model
logit Pðy ¼ 1Þ ¼ a0 þ 0:5X1 þ 0:5X2 þ b1Gc1 þ b2Gc2 þ.þ bpGcp;
where Gc1;G
c
2;.;G
c
p are again the genotypes for the causal rare
variants and bs are log ORs for the causal variants. We controlled
prevalence by a0 and set to it 1% unless otherwise stated. Under
both models, we set the magnitude of each bj to cjlog10MAFjj
such that rarer variants had larger effects. In the simulation
studies, for continuous traits, c ¼ 0.4, which gives the maximum
effect size jbjj ¼ 1.6 for variants with MAF ¼ 104 and small effects
jbjj ¼ 0.28 for MAF ¼ 0.2. For dichotomous traits, c ¼ ln5/4 ¼
0.402, which gives the ‘‘maximum’’ OR ¼ 5.0 (jbjj ¼ ln5) for vari-
ants with MAF ¼ 104 and smaller OR ¼ 1.32 for MAF ¼ 0.2. The
effect size curves are given in Figure S2.
We compared SKAT, an unsupervised variation on the WST13
that uses weighted-count-based collapsing, counting-based
collapsing,18 and CAST.14 For each of these tests, we considered
variants with observed MAF < 3% as rare: whether CAST collapses
depends on whether an individual exhibits any variants with
allele frequency < 3%, the counting method counts the number
variants with MAF < 3%, and the weighted count inflates the
contribution of each rare variant by multiplying the genotype
with the same beta-density-based weights as used in SKAT.
To accommodate missing genotypes commonly observed in
sequence data, we considered the effect of imputing missing
values by randomly setting 10% of the genotypes as missing,
imputing genotypes on the basis of observed allele frequencies
and Hardy-Weinberg equilibrium, and then applying SKAT to
the imputed data. We also performed restricted SKAT (rSKAT) by
applying unweighted SKAT to rare variants with MAF < 3%.
Note that for dichotomous phenotypes, rSKAT is essentially equiv-
alent to a covariate adjusted C-alpha test with the p value calcu-
lated analytically instead of via permutation. For each of the
methods, power was estimated as the proportion of p values < a,
where a ¼ 106 to mimic genome-wide studies.
Power and Sample-Size Formulae
To demonstrate the utility and accuracy of our power and sample-
size calculation method, we conducted several numerical experi-
ments. We first illustrated the use of the methods by computing
the sample size necessary to detect a 30 kb region with 5% of
the variants with MAF < 3% being causal. We assume effect size
(OR) increases with decreasing MAF, and seek 80% power at
significance levels a ¼ 106, 103, 102, corresponding to approx-
imate genome-wide sequencing significance and candidate-gene-sequencing studies of 50 and five genes, respectively. We consid-
ered both continuous and dichotomous traits.
TheTo show that the power estimated from our sample-size formula
is accurate, we compared empirical power for SKAT under simula-
tions to power estimated via our analytic method. Specifically, we
simulated continuous and case-control data under the same
setting as that used in the power simulations, and we estimated
power as a function of the sample size by computing the propor-
tion of p values < a ¼ 106 and compared the empirical power
curve to the power estimated by using our analytical method.
Results
Simulation of the Type I Error
The empirical type I error rates estimated for SKAT are pre-
sented in Table 1 for a ¼ 104, 105, and 106 and suggest
the type I error rate is protected for continuous pheno-
types, though for smaller sample sizes the SKAT can be
slightly conservative. For dichotomous phenotypes, SKAT
is conservative for smaller sample sizes and very small
a levels. Additional results from simulations of the type I
error for SKAT and the competing methods are presented
in Figure S3 for both continuous traits and dichotomous
traits and show that at larger a levels, all of the considered
tests correctly control at the a¼ 0.05 and 0.01 levels. These
results show that SKAT is a validmethod, and despite being
conservative at low a levels, SKAT maintains good power
relative to existing methods (see below). However, if
sample sizes are small or sharp control of type I error is
necessary, then standard permutation-based procedures
can be used to generate a Monte Carlo p value for signifi-
cance, though this can be computationally expensive
and does not work in the presence of covariates, such as
controlling for population stratification and require carful
modifications.
Statistical Power of SKAT and Competing Methods
We compared the power of SKAT with three burden tests
in a series of simulation studies for both continuous traits
and dichotomous traits by generating sequence data
in randomly selected 30 kb regions with a coalescent
model.37 For our primary power simulation, within each
region, 5% of variants with population MAF < 3% were
randomly chosen as causal, the effect size of causal variantswas a decreasing function of MAF, and 50%–100% of the
causal variants being positively associated with the trait
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Table 2. Characteristics of the 30 kb Region Data Sets Used in the
Simulation Studies
Average Number of Observed Variants
Sample Size (n)
500 1000 2500 5000
All traits* 255 330 438 512
Continuous trait** 9.6 13.3 18.6 22.3
Dichotomous trait (b 5 ¼ 100/0)** 14.4 18.7 23.5 25.2
Dichotomous trait (b5 ¼ 80/20)** 13.3 17.1 22.0 24.3
Dichotomous trait (b5 ¼ 50/50)** 11.1 14.9 19.7 22.6
The number of observed variants* and the number of observed causal
variants** within the region are averaged over the 1000 simulated data sets.(See Materials and Methods and Figure S2). The simulated
regions for our power analysis contained on average
605 variants (26 causal), of which 530.9 (88%), 502.9
(83%), and 422.8 (70%) had population MAF < 3%, < 1%,
and< 0.1%, respectively. The average allele frequency spec-
trum across the samples is similar to that of theDallas Heart
Studydata (Figure S4). Because themajority of variantshave
a low MAF, they might not be observed in any particular
sample. The average number of observed variants
(assuming no genotyping error) and the average number
of observed causal variants are presented in Table 2.
For continuous traits, SKAT had much higher power
than all the burden tests, and the weighted count method
tended to outperform the count and CAST methods
(Figure 1). SKAT’s power was robust to the proportion of
causal variants that were positively associated with the
trait, whereas the burden tests suffered substantial loss of
power when causal variants had the opposite effects. The
simulation results examining dichotomous traits were
qualitatively similar in that SKAT dominated the compet-
ing methods. However, here the power of the SKAT
decreased when both protective and harmful variants
were present, although less so than for the burden tests.
The difference in power for SKAT for different proportions
of protective variants is due to the fact that given fixed
population MAFs, protective variants imply negative log
ORs and lower disease risk and hence lower MAFs in cases
and more difficulties in observing rare variants in cases.
The larger decrease in power for the competing methods
is additionally driven by sensitivity to direction of effect
due to aggregation of genotypes. Across all configurations,
using imputed genotypes instead of the true genotype
for 10% missing genotype data led to a very small
reduction in power, despite the use of a very simple
Hardy-Weinberg-based imputation strategy. This is true
in part because most variants are rare.
Note that SKAT increases the weight of rare variants but
does not require thresholding. To show that the superior
performance of SKAT is intrinsic and is not driven by the
particular choice of the weight used, we calculated rSKAT,which does not weight the rare variants but instead uses
the same threshold as the burden tests. Our results, pre-
88 The American Journal of Human Genetics 89, 82–93, July 15, 2011sented in Figure 1, show that rSKAT is still substantially
more powerful than all three burden tests.
Power simulation results for other type I error rates (a ¼
0.01, 0.001), lower causal variant frequencies (population
MAF < 1%), and other region sizes (10 kb and 60 kb)
yielded the same conclusions (Figures S5–S8).
In the 30 kb genomic regions considered, reflecting anal-
ysis of genome-wide sequencing data, it is unlikely that
a large proportion of the rare variants are all causal.
However, for exome-scale sequencing, the number of
observed rare variants can be considerably smaller and
the proportion of causal rare variants can be greater.
Hence, we also conducted power simulations for smaller
region sizes (3 kb and 5 kb) and larger proportions of causal
variants (10%, 20%, and 50%). Results for both continuous
and dichotomous phenotypes are presented in Figures S9–
S12 and show that if 50% of the rare variants are causal and
that all of the causal variants have effects in the same direc-
tion, then SKAT and rSKAT are less powerful compared to
collapsing methods, with count-based collapsing having
the greatest power. This result held for both 3 kb and
5 kb regions and is expected because the collapsing
methods implicitly assume that all of the variants are
causal and have unidirectional effects. In all other settings
we considered, SKAT was the most powerful method.
Power and Sample-Size Estimation
To illustrate our power and sample-size calculation
method, in Figure 2 we present the estimated sample-size
curves as a function of maximum effect sizes (ORs for
dichotomous traits) necessary to detect a 30 kb region
with 5% of the variants with MAF < 3% being causal.
Table 3 presents estimated sample sizes for several configu-
rations of practical interest. Additional sample-size curves
when causal variants are rarer (MAF < 1%) or occur more
frequently (10% of variants are causal) or when prevalence
is varied (5%, 0.1%) can be found in Figures S13–S15.
These results show that, for a given region, one will
have more power (and a lower required sample size) to
detect rare causal variants if the percentage of variants
that are causal is higher, the causal rare variants have
higher MAFs and/or larger effect sizes (e.g., odds ratios
[ORs]), and the effects are more consistently in the same
direction. For case-control designs, lower prevalence
yields higher power because given the same OR and popu-
lation MAF, the lower prevalence results in enrichment of
more harmful (ORs > 1) variants, that is higher MAFs,
across both cases and controls, that is for rarer diseases
harmful rare variants are more likely to be observed.
Conversely, if the prevalence is low, fewer protective vari-
ants (ORs< 1), that is lower MAFs, are likely to be observed
in the sample.
We also compared the power and sample-size formulae
estimates to the empirical, simulation-based power esti-
mates for both continuous and dichotomous traits. Thecurves plotted in Figure 3 show that the empirical power
is accurately approximated by our analytical formula.
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Figure 2. Sample Sizes Required for Reaching 80% Power
Analytically estimated sample sizes required for reaching 80% power to detect rare variants associated with a continuous (top panel) or
dichotomous phenotype in case-control studies (half are cases) (bottom panel) at the a¼ 106, 103, and 102 levels, under the assump-
tion that 5% of rare variants with MAF < 3% within the 30 kb regions are causal. Plots correspond to 100%, 80%, and 50% of the causal
variants associated with increase in the continuous phenotype or risk of the dichotomous phenotype. Regression coefficients for the s
causal variants were assumed to be the same decreasing function of MAF as that in Figure 1. The absolute values of Required total sample
sizes are plotted again themaximumeffect sizes (ORs) whenMAF¼ 104. Estimated total sample sizes were averaged over 100 random30Application to Dallas Heart Study Data
We analyzed sequence data on 93 variants in ANGPTL3
(MIM 604774), ANGPTL4 (MIM 605910), and ANGPTL5
(MIM 607666) in 3476 individuals from the Dallas Heart
Study38 to test for association between log-transformed
serum triglyceride (logTG) levels and rare variants in these
genes. We adjusted for sex and ethnicity (black, Hispanic,
or white) but did not adjust for age as a large number of
subjects have missing ages. In addition to testing for asso-
kb regions.ciation via SKAT and the three burden tests considered
earlier, we also applied the permutation-based varying-
Table 3. Required Total Sample Size to Achieve 80% Power to Detect
Case-Control Phenotype at the Genome-wide Level a ¼ 106
Total Sample Size
Maximum b ¼ 1.6/ Maximu
5% Causal 10%
Continuous trait 5,990 1,80
Dichotomous trait with prevalence 10% 15,120 4,81
Dichotomous trait with prevalence 1% 12,030 3,87
Power was estimated via the analytical formulae assuming 5% or 10% of varian
were assumed to be a decreasing function of MAF, jbjj ¼ c jlog10MAFjj (j ¼ 1,.,s)
total sample sizes (cases and controls) are given for different ‘‘maximum’’ effect size
Estimated sample sizes were averaged over 100 random 30 kb regions.
Thethreshold method (VT) and the Polyphen-score-adjusted
VT (VTP),16 which are based on the residuals obtained
from regressing the phenotype on the covariates and
assume gene-covariate independence. Because VT and
VTP require permutation, they are computationally expen-
sive when applied genome wide. For VTP, we used the
Polyphen score for rare variants (MAF< 0.01) and assigned
a constant score of 0.5 to all other variants. We also
analyzed a dichotomized phenotype on the highest andlowest quartiles of each of the six sex-ethnicity groups
(Table 4).
Rare Variants Associated with a Continuous or Dichotomous
m OR ¼ 5 Maximum b ¼ 1.9/ Maximum OR ¼ 7
Causal 5% Causal 10% Causal
0 4,260 1,290
0 9,650 3,120
0 7,010 2,290
ts with MAF < 3% are causal. Regression coefficients for the s causal variants
, where 80% of bj’s are positive and 20% are negative; see Figure S2. Required
s (or ORs) whenMAF¼ 104 and different prevalences for case-control studies.
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Figure 3. Power Comparisons Based on
Simulation and Analytic Estimation
Power as a function of total sample size
estimated by simulation with 1000 repli-
cates and by the proposed power formula
for continuous and dichotomous case-
control traits. Simulation configurations
correspond to those used in Figure 1, in
which 80% of the regression coefficients
for the causal rare variants were positive.SKAT was by far the most powerful test for the dichoto-
mous trait. For continuous traits, SKAT has much smaller
p values than two burden methods (CAST and WST) and
VT, and has a slightly higher p value than the counting-
based burden test (N) and VTP. Note that SKAT was easier
to apply because it did not require prior functional infor-
mation (available for only a subset of variants) or permuta-
tion, and it adjusted for covariates without assuming gene-
covariate independence.
Computation Time
The computation time for the SKAT depends on the
sample size and the number of markers. To analyze a 30 kb
region sequenced on 1000, 2500, or 5000 individuals,
SKAT required 0.21, 0.73, and 2.3 s, respectively, for
continuous traits and ~20% longer for dichotomous traits,
on a 2.33 GHz laptop with 6 Gb memory. Analyzing
300 kb, 3Mb, or 3 Gb (the entire genome) on 1000 individ-
uals requires 2.5 s, 25 s, and 7 hr, respectively.
Discussion
We propose SKAT as a supervised, flexible, and computa-
tionally efficient statisticalmethod that tests for association
between a continuous or dichotomous phenotype and rare
and common genetic variants in sequencing-based associa-
tion studies. We demonstrate that SKAT’s power is greater
than that of several burden tests over a range of genetic
models. Furthermore, we have developed analytical powerand sample-size calculations for SKAT that assist in
designing sequencing-based association studies.
Table 4. Analysis of the Dallas Heart Study Sequencing Data
SKAT C N W
Continuous TG level 9.5 3 105 1.9 3 103 7.2 3 105 2.3 3 10
Dichotomized TG level 1.3 3 104 3.2 3 102 2.2 3 103 3.1 3 10
Analysis of the Dallas Heart Study sequencing data with SKAT, the weighted sum burden test (W), the countin
varying-threshold method (VT), and the Polyphen-score adjusted VT (VTP) method. Beta (1, 25) is used as th
a p values are estimated on the basis of 106 permutations.
estimate in the abse
covariates, for exam
90 The American Journal of Human Genetics 89, 82–93, July 15, 2011Like burden tests, SKAT performs
region-based testing. However, SKAT
has several major advantages over theexisting tests. As a supervisedmethod,
SKAT directly performs multiple re-
gressions of a phenotype on genotypes for all variants in
the region, adjusting for covariates. Hence, as with conven-
tional multiple regression models, neither directionality
nor magnitudes of the associations are assumed a priori
but are instead estimated from the data. To test efficiently
for the joint effects of rare variants in the region on the
phenotype, SKAT assumes a distribution for the regression
coefficients of the markers, whose variances depend on
flexible weights. SKAT performs a score-based variance-
component test, whose calculation only requires fitting
the null model by regressing phenotypes on covariates
alone and computing p values analytically. The flexible
regression framework also allows us to allow for epistatic
effects.
Besides region-based analysis, SKAT can also be applied
to any biologically meaningful SNP set. As SKAT is a regres-
sion-based method, it can be easily extended to survival,
and longitudinal and multivariate phenotypes and hence
provides a comprehensive framework for a wide variety
of sequencing-based association studies.
The ability to obtain a p value directly without the need
for permutation is an attractive feature of SKAT, and allows
for rapid estimation of p values in exome and genome-
wide sequencing studies. Our simulations showed that
for continuous phenotype, the p values are accurate
when the sample size is moderate or large; for dichoto-
mous phenotypes, the p values are conservative at lower
a levels (e.g., < 104) if the sample size is modest or
small. Permutation can be used to obtain a more accurateVTa VTPa
4 3.5 3 104 2.0 3 105
3 8.6 3 103 2.1 3 103
g-based burden test (N), the CAST method (C), the
e weight in the SKAT and the weighted sum test.
nce of covariates. In the presence of
ple population stratification, standard
permutations fail and require careful modifications.
Despite the conservative nature of the score test, SKAT
often still has higher power than competing methods at
small a levels.
SKATcan be combined with collapsing strategies to form
a hybrid testing approach. If most of the variants within
a range of allele frequencies are causal and have the same
directionality (i.e., under settings that are optimal for
burden-based tests), collapsing these variants and then
applying SKAT to the collapsed variants can improve
power. For example, because singletons are common in
sequencing studies (57 of 93 variants in the Dallas Heart
Study data), a possible hybrid strategy is to first collapse
all of the singletons into a single value and then apply
SKAT to the collapsed value and the other 36 variants.
Compared to the original SKAT, this strategy gives a slightly
lower p value, 3.1 3 105, for the continuous trait and
a slightly higher p value, 1.6 3 104, for the dichotomous
trait. Simulation studies showed that the two methods are
of similar power under the settings we used to generate
Figure 1.
An important feature of SKAT is that it allows for incor-
poration of flexible weight functions to boost analysis
power, for example by increasing the weight of variants
with lower MAFs and decreasing the weight of information
from variants inferred with lower confidence. Good
choices of weights are likely to improve the power of the
association test with SKAT, although simulations show
that even equal weights can yield high power when
combined with thresholding. In our simulation studies,
we employed a class of flexible continuous weights as
a function of MAF by using the beta function, which
increases the weight of rare variants and does not require
thresholding. Users can define other types of weight func-
tions. To further improve analysis power, one can estimate
weights by incorporating information besides MAF, for
example by using the Polyphen score or integrating other
annotation information, which will become increasingly
available as our understanding of genome variation
improves. Therefore, because of its flexibility, SKAT hasthe capacity to mature, and its power to increase, as the
field progresses.Appendix A
Estimating the Null Distribution for Q
Under the null hypothesis, Q follows a mixture of chi-
square distributions.29,30 More specifically, we define P0 ¼
VV ~Xð ~X0V ~XÞ1 ~X0V where ~X is the n 3 (p þ 1) matrix
equal to [1, X]. For continuous phenotypes, V ¼ bs20I
where bs0 is the estimator of s under the null model where
f(G) ¼ 0, and I is an n 3 n identity matrix. For dichoto-
mous phenotypes, V ¼ diagðbm01ð1 bm01Þ; bm02ð1 bm02Þ;.;bm0nð1 bm0nÞÞ where bm0i ¼ logit1ðba þ ba0XiÞ is the esti-
mated probability that the i-th subject is a case under the
null model. Then under the null model
ThenQ 
X
i¼1
lic
2
1;i; (Equation 6)
where (l1, l2,., ln) are the eigenvalues of P
1=2
0 KP
1=2
0 , and
c21;i are independent c
2
1 random variables.
Several approximation and exact methods have been
suggested to obtain the distribution of Q.39 Among these,
the Davies exact method,26 based on inverting the charac-
teristic function of Equation 6, appears to work well in
practice and is used here.
SKAT Is a Generalization of the C-Alpha Test
The recently proposed the C-alpha test has advantages
over burden tests in that it explicitly models the possibility
that minor alleles can be deleterious or protective.
However, it does not currently allow for the analysis of
quantitative outcomes or the inclusion of covariates and
p value calculation requires permutation. We demonstrate
that for a dichotomous trait in the absence of covariates,
the C-alpha test statistic is equivalent to the SKAT statistic
with unweighted linear kernel, which is the same as the
kernel machine test in Wu et al.24
Suppose the j-th variant is observed dj times in the cases,
out of nj times total in cases and controls, and that
p0 ¼
Pn
i¼1yi=n. For a dichotomous trait and no covariates,
the C-alpha test statistic
Ta ¼
Xp
j¼1
h
dj  njp0
2njp01 p0
i
(Equation 7)
Denote T1a ¼
Pp
j¼1ðdj  njp0Þ2. Because
Pp
j¼1njp0ð1 p0Þ
is the mean of Ta under the null hypothesis of no associa-
tion,T1a is theC-alpha test statisticwithoutmeancentering.
Because dj ¼ y0G:j and nj ¼ J0G:j, where G:j is the j-th
column of the genotype matrix G and J ¼ ð1;1;.;1Þ0, it
can be easily shown that
T1a ¼

y p0J
0
GG0

y p0J

: (Equation 8)
Note that under the unweighted linear kernel, K ¼ GG’
and bm0 ¼ p0J if no covariates are present. Hence, Equation
8 is identical to Equation 3, that is T1a is equivalent to the
SKAT test statistic with unweighted linear kernel.
Although the SKAT statistic with unweighted linear
kernel and the C-alpha test statistic are equivalent, SKAT
and C-alpha test use different null distributions to assess
significance: C-alpha test uses a normal approximation,
whereas we use a mixture of chi-squares. The normal
approximation gives a valid p value when the tested rare
variants are independent and sample sizes are large, and
so requires an assumption of linkage equilibrium. In the
presence of LD, permutation is used by the C-alpha test
for significance testing. One can easily see that the test
statistic takes a quadratic formof y, which follows amixture
of chi-square distributions. SKAT approximates this distri-
bution directly with the Davies method and hence givesaccurate estimation of significance regardless of the LD
structure when sample size is sufficient.
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